Skip to main content

This website is intended exclusively for healthcare professionals residing and/or working in the UAE.

  1. Article
  2. Source: Campus Sanofi
  3. 24 Apr 2026

FLUNITY-HD

Author: Sanofi

Editorial Team

The FLUNITY-HD Study is the largest individually randomized influenza vaccine effectiveness study and the first of its kind for an influenza vaccine. The study demonstrates the superior benefit of HD-IIV, specifically developed for older adults, compared with SD-IIV against a wide range of hospitalization outcomes in a prespecified and powered analysis encompassing nearly half a million participants. Providing the high-quality data, this study provides further critical evidence that widespread use of HD-IIV could substantially reduce the burden of influenza on both older adults and healthcare systems globally.

FLUNITY-HD Study Definitively Demonstrated the Superior Protection Beyond Flu of High-Dose Flu Vaccine vs Standard-Dose Flu

FLUNITY-HD is the largest ever individually randomised influenza vaccine effectiveness study, with nearly half a million older adults across multiple seasons

FLUNITY-HD joins a growing body of data demonstrating the superiority of high-dose vaccine

Make high-dose flu vaccine your choice for protection beyond flu.

 

FLUNITY-HD: Expanding Protection Beyond Flu

FLUNITY-HD is the largest flu vaccine study of its kind
466K
+
Total Older Adults
Prespecified pooled analysis of
2
Individually Randomised Studies
3
Diverse Flu Seasons*

This GROUNDBREAKING STUDY adds to the vast body of evidence showing the superior protection beyond flu of high-dose flu vaccine

The ONLY high-dose flu vaccine to demonstrate superior protection against both flu infection and its complications in robust, individually randomised studies†

Over 15 years of evidence in more than 45 million older adults

A well-established safety profile

FLUNITY-HD provides public health decision-makers and healthcare professionals the clinical confidence needed to recommend high-dose flu vaccine for older adults,‡ and to make informed choices for patients and their families

Prof. Tor explaining FLUNITY-HD data

FLUNITY-HD Cardiovascular Outcomes

MAT-BH-2600249  

Related

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.
SitemapLegal noticePrivacy PolicyCookie PolicyContactAccessibility statement

© Sanofi 2004-2026 - All rights reserved

MAT-AE-2100444/V8/JUL2025

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.
SitemapLegal noticePrivacy PolicyCookie PolicyContactAccessibility statement

© Sanofi 2004-2026 - All rights reserved

MAT-AE-2100444/V8/JUL2025